Narlaprevir

DRUG6 trials

Sponsors

Merck Sharp & Dohme LLC, R-Pharm

Conditions

Chronic Hepatitis C Genotype 1bChronic Hepatitis c Genotype 1HealthyHepacivirusHepatic ImpairmentHepatitis CHepatitis C, Chronic

Phase 1

A Drug Interaction Study to Assess the Pharmacokinetics of Narlaprevir and Antiretroviral Drugs

CompletedNCT03537404

Start: 2017-04-24End: 2017-06-30Updated: 2019-02-19

A Pharmacokinetic Study of Narlaprevir as a Single Dose or With Ritonavir Combination in Patients With Hepatic Impairment and Healthy Matched Volunteers

CompletedNCT03832426

R-PharmHepatic Impairment

Start: 2013-11-08End: 2014-10-24Updated: 2019-05-22

Phase 2

Three-year Follow-up of Participants After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063)

TerminatedNCT00689390

Merck Sharp & Dohme LLCHepacivirus, Hepatitis C, Chronic

Start: 2007-02-20End: 2014-10-13Updated: 2018-09-11

Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Daclatasvir in Treatment-Naїve Patients With Chronic Hepatitis C Genotype 1b

CompletedNCT03485846

R-PharmChronic Hepatitis C Genotype 1b

Start: 2017-11-27End: 2018-11-21Updated: 2018-12-19

Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Sofosbuvir in Treatment-naïve Patients With Chronic Hepatitis C Genotype 1

CompletedNCT04246723

R-PharmChronic Hepatitis c Genotype 1

Start: 2019-05-06End: 2020-08-12Updated: 2022-10-31

Phase 3

Efficacy and Safety of Narlaprevir Used in Combination With Ritonavir in Treatment-Naïve and Failed Prior Treatment With Pegylated Interferon/Ribavirin Patients With Chronic Hepatitis C Genotype 1 (PIONEER - Study)

CompletedNCT03833362

R-PharmHepatitis C

Start: 2014-05-07End: 2017-02-21Updated: 2019-02-07

Related Papers

Primer ID Ultra-Deep Sequencing Reveals Dynamics of drug Resistance-Associated Variants in Breakthrough Hepatitis C Viruses: Relevance to Treatment Outcome and Resistance Screening

UNC Libraries2025-10-16

Primer ID Ultra-Deep Sequencing Reveals Dynamics of drug Resistance-Associated Variants in Breakthrough Hepatitis C Viruses: Relevance to Treatment Outcome and Resistance Screening

Antiviral Therapy2015-10-017 citations